Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

634 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab.
Martini G, Ciardiello D, Dallio M, Famiglietti V, Esposito L, Corte CMD, Napolitano S, Fasano M, Gravina AG, Romano M, Loguercio C, Federico A, Maiello E, Tuccillo C, Morgillo F, Troiani T, Di Maio M, Martinelli E, Ciardiello F. Martini G, et al. Among authors: di maio m. Int J Cancer. 2022 Aug 1;151(3):473-480. doi: 10.1002/ijc.34033. Epub 2022 Apr 29. Int J Cancer. 2022. PMID: 35429341 Free PMC article. Clinical Trial.
Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial.
Pacilio C, Morabito A, Nuzzo F, Gravina A, Labonia V, Landi G, Rossi E, De Maio E, Di Maio M, D'Aiuto G, Botti G, Normanno N, Chiodini P, Gallo C, Perrone F, de Matteis A; NCI-Naples Breast Cancer Group. Pacilio C, et al. Among authors: di maio m. Br J Cancer. 2006 May 8;94(9):1233-6. doi: 10.1038/sj.bjc.6603096. Br J Cancer. 2006. PMID: 16622454 Free PMC article. Clinical Trial.
Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study.
Gridelli C, Gallo C, Ceribelli A, Gebbia V, Gamucci T, Ciardiello F, Carozza F, Favaretto A, Daniele B, Galetta D, Barbera S, Rosetti F, Rossi A, Maione P, Cognetti F, Testa A, Di Maio M, Morabito A, Perrone F; GECO investigators. Gridelli C, et al. Among authors: di maio m. Lancet Oncol. 2007 Jun;8(6):500-12. doi: 10.1016/S1470-2045(07)70146-8. Lancet Oncol. 2007. PMID: 17513173 Clinical Trial.
Second-line treatment of advanced non-small cell lung cancer.
Gridelli C, Ardizzoni A, Ciardiello F, Hanna N, Heymach JV, Perrone F, Rosell R, Shepherd FA, Thatcher N, Vansteenkiste J, De Petris L, Di Maio M, De Marinis F. Gridelli C, et al. Among authors: di maio m. J Thorac Oncol. 2008 Apr;3(4):430-40. doi: 10.1097/JTO.0b013e318168c815. J Thorac Oncol. 2008. PMID: 18379366 Free article. Clinical Trial.
Weekly docetaxel vs. docetaxel-based combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer patients. The DISTAL-2 randomized trial.
Gebbia V, Gridelli C, Verusio C, Frontini L, Aitini E, Daniele B, Gamucci T, Mancuso G, Di Maio M, Gallo C, Perrone F, Morabito A. Gebbia V, et al. Among authors: di maio m. Lung Cancer. 2009 Feb;63(2):251-8. doi: 10.1016/j.lungcan.2008.05.027. Epub 2008 Jul 15. Lung Cancer. 2009. PMID: 18632181 Clinical Trial.
Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trials.
Gridelli C, Morabito A, Gebbia V, Mencoboni M, Carrozza F, Viganò MG, Verusio C, Bollina R, Mattioli R, Valerio MR, Valmadre G, Maione P, Rossi A, Cascone T, Morgillo F, Di Maio M, Piccirillo MC, Gallo C, Perrone F, Ciardiello F. Gridelli C, et al. Among authors: di maio m. Lung Cancer. 2010 Jan;67(1):86-92. doi: 10.1016/j.lungcan.2009.03.021. Lung Cancer. 2010. PMID: 19380175 Clinical Trial.
Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study.
Colucci G, Labianca R, Di Costanzo F, Gebbia V, Cartenì G, Massidda B, Dapretto E, Manzione L, Piazza E, Sannicolò M, Ciaparrone M, Cavanna L, Giuliani F, Maiello E, Testa A, Pederzoli P, Falconi M, Gallo C, Di Maio M, Perrone F; Gruppo Oncologico Italia Meridionale (GOIM); Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente (GISCAD); Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC). Colucci G, et al. Among authors: di maio m, di costanzo f. J Clin Oncol. 2010 Apr 1;28(10):1645-51. doi: 10.1200/JCO.2009.25.4433. Epub 2010 Mar 1. J Clin Oncol. 2010. PMID: 20194854 Clinical Trial.
Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study.
Gridelli C, Morgillo F, Favaretto A, de Marinis F, Chella A, Cerea G, Mattioli R, Tortora G, Rossi A, Fasano M, Pasello G, Ricciardi S, Maione P, Di Maio M, Ciardiello F. Gridelli C, et al. Among authors: di maio m. Ann Oncol. 2011 Jul;22(7):1528-1534. doi: 10.1093/annonc/mdq630. Epub 2011 Jan 6. Ann Oncol. 2011. PMID: 21212155 Free article. Clinical Trial.
634 results